GRA President and CEO Susan Shows to Retire with 22-Year Legacy

Tenure marked by shaping all major aspects of the organization

Susan Shows headshot

A driving factor in the development and success of the Georgia Research Alliance over a tenure that has spanned more than two decades, President and CEO Susan Shows today announced her retirement from the Alliance at the fall meeting of GRA’s Board of Trustees.

Since joining GRA in 2001 as vice president, Shows was instrumental in shaping each of the organization’s areas of operation. She worked closely with member universities to bring top scientific talent to their campuses, playing an active role in the recruitment of most of GRA’s 78-member Academy of Scientists. She also partnered with university leaders to identify “best investments” in high-tech lab equipment and core research facilities to make Georgia’s institutions more competitive in winning lucrative research grants and contracts.

And 20 years ago, she served as chief architect of GRA’s venture development program, a multi-faceted enterprise that has helped launch 240 high-potential startup companies with operations in Georgia, all based on inventions made by university scientists in Georgia.

While serving in the senior vice president role, Shows placed collaboration and impact at the center of these and other activities. She often brokered working partnerships among scientists and universities and between academia and industry. And she developed the statistical framework for providing funders with an accountability of GRA’s performance and its return on the state’s investment in GRA programs.

Since being named president and CEO of GRA in September 2020, Shows has continued to grow GRA’s talent, infrastructure and entrepreneurship programs while also launching several initiatives that leverage university research strengths to address areas of priority for the state.  

“GRA owes so much of its success to Susan, and it would not be the organization it is today without her,” says GRA Board Chair David Ratcliffe. “Her early work in GRA’s program areas was both foundational and durable. As president and CEO, she has brought a new level of agility to the Alliance by creating and seizing opportunities to make an impact in agricultural technology, artificial intelligence, Sickle Cell Disease and workforce development.  And the taxpayers of Georgia should be pleased to know that GRA’s return on investment grew to $13 billion this year.”

Shows will continue to serve in an advisory role until the end of GRA’s fiscal year next June. In reflecting on her tenure with the Alliance, Shows said: “GRA works in so many different ways for the single purpose of growing Georgia’s economy. It has been a great privilege to have been a part of this unique organization, and to have worked on teams of true professionals in government, industry and academia, all to benefit Georgia’s excellent universities and the state as a whole.”

GLS 2025 Year in Review

December 22, 2025
Dear Georgia Life Sciences Community, As we reflect on the past year, I want to extend my sincere thanks to our Georgia Life Sciences members for making it such an impactful one. Your engagement and leadership continue to move our industry forward and advance our shared strategic priorities— driving strong policy, expanding the talent pipeline, and creating intentional spaces for collaboration across Georgia’s life sciences ecosystem. Our Year in Review captures the progress we’ve made together across these priorities and highlights the collective impact our members are having statewide—from strengthening the workforce and supporting manufacturing growth to elevating Georgia’s position as a national life sciences leader. This progress is only possible because of the collaboration, commitment, and insight of our member community. 

Investing in America’s Biopharmaceutical Infrastructure Strengthens the Economy and Supports Union Workers

By Maria Thacker Goethe • December 20, 2025
The biopharmaceutical industry is growing America’s manufacturing and R&D capabilities to develop the next generation of treatments. A recent study from PILMA quantified the impact of the industry’s investment in American infrastructure on the economy and union workforce across 18 states from 2019-2024. The study found that across the 18 states included, the biopharmaceutical industry: Supported the American economy by investing $86.5B in R&D and manufacturing infrastructure and developing 1000+ construction projects at over 700 distinct facilities. Strengthened the American workforce by generating $2.6B in skilled union wages and providing $19M in support for union apprenticeships. The impact of the biopharmaceutical industry’s investment in American manufacturing and union jobs extends beyond direct benefits, spurring additional economic activity in the communities where workers live. This is known as the multiplier effect . On average, every $1 of new investment in a U.S. biopharmaceutical manufacturing facilities generates an additional $1.59 in further economic activity (2.59x times the initial investment value). The industry’s $86.5B investment in R&D and manufacturing infrastructure has a total economic impact of $224B. Check out this resource to learn more about how biopharmaceutical investment in American infrastructure supports America’s workers and communities. For more on how biopharmaceutical companies are investing in America’s future, visit innovation.org/america-investment .

Georgia Life Sciences Joins National Coalition Urging Congressional Action on Key Innovation Policies

December 10, 2025
Georgia Life Sciences has joined 43 state and regional life sciences organizations in signing a national Council of State Bioscience Associations (CSBA) letter calling on Congress to take immediate action on three bipartisan policy priorities that are essential to sustaining U.S. leadership in biomedical innovation and supporting patients nationwide. With Congress back in session and several critical programs at risk of expiring, the letter urges congressional leaders to advance the following provisions without delay: 1. Reauthorize the Rare Pediatric Disease Priority Review Voucher (PPRV) Program The PPRV program has been instrumental in incentivizing the development of therapies for children with rare and life-threatening conditions. Its lapse threatens to slow or halt research that families across the country are counting on. 2. Extend the SBIR/STTR Programs The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs provide crucial early-stage capital for emerging biotech and medtech companies—many of them in Georgia. Without reauthorization, hundreds of innovative small businesses face uncertainty, jeopardizing new therapies, diagnostics, and technologies in the pipeline, 3. Advance PBM Transparency Reforms Greater transparency and accountability within pharmacy benefit manager (PBM) practices are needed to ensure that savings reach patients and employers. Reforming PBM operations is essential to strengthening access and affordability across the healthcare system. A Unified Message from the Life Sciences Community The sign-on letter reflects broad, bipartisan alignment across the national life sciences ecosystem: researchers, entrepreneurs, investors, patient advocates, and state associations all share a common message— these programs underpin America’s global competitiveness and are vital to patients who rely on continued scientific progress. Georgia Life Sciences has shared the letter with members of Georgia’s congressional delegation and will continue engaging with policymakers to emphasize the importance of swift action.
MORE POSTS